- Home
- DEA vs AUPH Comparison
DEA vs AUPH Comparison
Compare DEA & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEA
- AUPH
- Stock Information
- Founded
- DEA 2011
- AUPH 1993
- Country
- DEA United States
- AUPH Canada
- Employees
- DEA N/A
- AUPH N/A
- Industry
- DEA Real Estate Investment Trusts
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- DEA Real Estate
- AUPH Health Care
- Exchange
- DEA Nasdaq
- AUPH Nasdaq
- Market Cap
- DEA 1.3B
- AUPH 1.0B
- IPO Year
- DEA 2015
- AUPH 1999
- Fundamental
- Price
- DEA $12.48
- AUPH $8.77
- Analyst Decision
- DEA Buy
- AUPH Strong Buy
- Analyst Count
- DEA 2
- AUPH 3
- Target Price
- DEA $14.50
- AUPH $10.33
- AVG Volume (30 Days)
- DEA 1.4M
- AUPH 1.4M
- Earning Date
- DEA 11-05-2024
- AUPH 11-07-2024
- Dividend Yield
- DEA 8.49%
- AUPH N/A
- EPS Growth
- DEA N/A
- AUPH N/A
- EPS
- DEA 0.17
- AUPH N/A
- Revenue
- DEA $302,121,000.00
- AUPH $220,361,000.00
- Revenue This Year
- DEA N/A
- AUPH $36.52
- Revenue Next Year
- DEA $7.29
- AUPH $19.02
- P/E Ratio
- DEA $73.61
- AUPH N/A
- Revenue Growth
- DEA 2.98
- AUPH 38.72
- 52 Week Low
- DEA $10.94
- AUPH $4.71
- 52 Week High
- DEA $14.53
- AUPH $9.74
- Technical
- Relative Strength Index (RSI)
- DEA 36.39
- AUPH 71.82
- Support Level
- DEA $11.53
- AUPH $7.87
- Resistance Level
- DEA $13.67
- AUPH $8.70
- Average True Range (ATR)
- DEA 0.37
- AUPH 0.38
- MACD
- DEA -0.12
- AUPH 0.04
- Stochastic Oscillator
- DEA 42.19
- AUPH 96.67
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.